Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MAIA Biotechnology, Inc. Common Stock (NY:MAIA)

1.190 +0.020 (+1.71%)
Delayed Quote Updated: 9:42 AM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,243
Open 1.190
Bid (Size) 1.190 (1,100)
Ask (Size) 1.210 (1,100)
Prev. Close 1.170
Today's Range 1.190 - 1.210
52wk Range 0.8700 - 3.190
Shares Outstanding 37,032,307
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What's going on in today's session ↗
Via Chartmill
These stocks are moving in today's session ↗
Via Chartmill

Performance

YTD
-25.6%
-25.6%
1 Month
-8.5%
-8.5%
3 Month
-17.9%
-17.9%
6 Month
-10.5%
-10.5%
1 Year
-28.3%
-28.3%

More News

Read More
Which stocks are gapping on Tuesday? ↗
Via Chartmill
Which stocks are moving before the opening bell on Tuesday? ↗
Via Chartmill
News headline image
Which stocks are gapping on Monday? ↗
Via Chartmill
News headline image
Biotech Giant MAIA Biotechnology (NYSE American: MAIA) Dives Headfirst into Crypto with Audacious Treasury Strategy
Via BreakingCrypto
Topics ETFs Economy
News headline image
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion
Via FinancialNewsMedia
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Via Benzinga
News headline image
MAIA Biotechnology Receives FDA’s Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA’s New Agreement With Big Pharma Roche Turns Retail Investors Bullish As Stock Soars ↗
Via Stocktwits
News headline image
MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology to Present at BIO International Convention 2025
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients ↗
Via Benzinga
News headline image
MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial
From MAIA Biotechnology
Via Business Wire
News headline image
MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
CORRECTING and REPLACING MAIA Biotechnology Announces Private Placement of Approximately $695,000
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology Announces Director Participation in Recent Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology Announces $1.08 Million Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
News headline image
MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders
From MAIA Biotechnology, Inc.
Via Business Wire

Frequently Asked Questions

Is MAIA Biotechnology, Inc. Common Stock publicly traded?
Yes, MAIA Biotechnology, Inc. Common Stock is publicly traded.
What exchange does MAIA Biotechnology, Inc. Common Stock trade on?
MAIA Biotechnology, Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for MAIA Biotechnology, Inc. Common Stock?
The ticker symbol for MAIA Biotechnology, Inc. Common Stock is MAIA on the New York Stock Exchange
What is the current price of MAIA Biotechnology, Inc. Common Stock?
The current price of MAIA Biotechnology, Inc. Common Stock is 1.190
When was MAIA Biotechnology, Inc. Common Stock last traded?
The last trade of MAIA Biotechnology, Inc. Common Stock was at 10/02/26 09:42 AM ET
What is the market capitalization of MAIA Biotechnology, Inc. Common Stock?
The market capitalization of MAIA Biotechnology, Inc. Common Stock is 44.07M
How many shares of MAIA Biotechnology, Inc. Common Stock are outstanding?
MAIA Biotechnology, Inc. Common Stock has 44M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.